Cytoreductive Nephrectomy and Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives
Authors:
- Luigi NapolitanoLNLuigi Napolitano
- Celeste ManfrediCeleste Manfredi
- Luigi CirilloLCLuigi Cirillo
- Giovanni Maria FuscoGFGiovanni Maria Fusco
- Francesco PassaroFPFrancesco Passaro
- Marco AbateMAMarco Abate
- Roberto La RoccaRRRoberto La Rocca
- Francesco MastrangeloFMFrancesco Mastrangelo
- Lorenzo SpiritoLSLorenzo Spirito
- Savio Domenico PandolfoSavio Domenico Pandolfo
- Felice CrocettoFCFelice Crocetto
- Davide ArcanioloDADavide Arcaniolo
Open Access
Abstract
In the past decades, several treatments have been proposed for the management of metastatic renal cell carcinoma (mRCC). Among these, cytoreductive nephrectomy (CN) represents a controversial and open issue in the era of targeted therapy and novel immunotherapy with immune checkpoint inhibitors. Two important studies, CARMENA and SURTIME, analyzed therapy with sunitinib with or without CN, and immediate CN followed by sunitinib versus a deferred CN after three cycles of sunitinib, respectively. CARMENA showed the non-inferiority of sunitinib alone versus sunitinib plus CN, whereas SURTIME showed no difference in progression-free survival (PFS), but a better median OS among patients with deferred CN. Therefore, more prospective clinical trials and appropriate patient identification are necessary to support CN in this new scenario. This review provides a snapshot of the current evidence for CN in mRCC, discusses the management strategies, and offers perspectives on the direction of future research.Keywords
This publication has 49 references indexed in Scilit:
- Disease-Specific Survival in De Novo Metastatic Renal Cell Carcinoma in the Cytokine and Targeted Therapy EraPLOS ONE, 2013
- Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinomaBMC Cancer, 2011
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter StudyJournal of Clinical Oncology, 2009
- Thirty-Day Mortality After Nephrectomy: Clinical Implications for Informed ConsentEuropean Urology, 2009
- Initial Experience With Robot Assisted Partial Nephrectomy for Multiple Renal MassesJournal of Urology, 2009
- The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal CarcinomaClinical Cancer Research, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Validation and Extension of the Memorial Sloan-Kettering Prognostic Factors Model for Survival in Patients With Previously Untreated Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2005
- Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer: A Combined AnalysisJournal of Urology, 2004
- Spontaneous regression of metastatic renal cell carcinomaUrology, 1982